Limited doses of immunotherapy use in advanced non-small cell lung cancer elderly patients with ECOG of 2 and high PDL-1 expression

Pui Yee Wong; Soon Hin How; Radhiana Hassan; Muhammad Naimmuddin Abdul Azih

doi:10.1002/agm2.12179

Limited doses of immunotherapy use in advanced non-small cell lung cancer elderly patients with ECOG of 2 and high PDL-1 expression

Aging Med (Milton). 2021 Oct 24;4(4):345-349. doi: 10.1002/agm2.12179. eCollection 2021 Dec.

Authors

Pui Yee Wong¹, Soon Hin How², Radhiana Hassan³, Muhammad Naimmuddin Abdul Azih²

Affiliations

¹ Department of Respiratory Medicine Hospital Tengku Ampuan Afzan Kuantan Malaysia.
² Department of Medicine Kulliyyah of Medicine International Islamic University Malaysia Kuantan Malaysia.
³ Department of Radiology Kulliyyah of Medicine International Islamic University Malaysia Kuantan Malaysia.

Abstract

Immunotherapy is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with high PDL-1 expression. Here, we report three such patients with durable response despite limited doses immunotherapy.

Keywords: durable response; high PD‐L1; immunotherapy; poor ECOG; short duration.

Publication types

Case Reports